Early market access decisions are key for biotech commercialization success

Sharon Cunningham, co-founder and CEO of Shorla Oncology, along with Faruk Abdullah, president, professional services & CBO, Eversana, shared a case study on one path to commercialization.

Cunningham told the Biotech Showcase audience that there is a need for a clear commercialization strategy from the outset, including market access choices of product market fit and strategy to get to market. She believed that this information and clear strategy positively impacted the companies valuation and investment opportunities.

The company chose Eversana and its co-commercialization model to support its path to market for various reasons including training, experience with the US market, determining market access choices that drove value, as well as its flexibility.

Cunningham shared her lessons learned, including and earlier investment in market access and market research.

Abdullah also shared that market access choices are dependent on market dynamics with the product. However, it was beneficial to discuss pricing and reimbursement in Phase II or Phase III.

Please read the full article on the Informa Life Sciences media brand BioXconomy.

@Depositphotos/vaeenma